Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Kaposi | 7 | 2023 | 120 | 1.690 |
Why?
|
| Histiocytosis, Langerhans-Cell | 5 | 2024 | 221 | 1.580 |
Why?
|
| Hodgkin Disease | 2 | 2023 | 293 | 1.190 |
Why?
|
| Residence Characteristics | 4 | 2024 | 269 | 0.790 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2021 | 804 | 0.780 |
Why?
|
| Insurance Coverage | 4 | 2010 | 121 | 0.780 |
Why?
|
| Maternal Exposure | 3 | 2019 | 148 | 0.770 |
Why?
|
| Air Pollutants | 3 | 2019 | 101 | 0.760 |
Why?
|
| Case-Control Studies | 12 | 2023 | 3251 | 0.750 |
Why?
|
| Insurance, Health | 3 | 2010 | 138 | 0.720 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2019 | 3083 | 0.690 |
Why?
|
| Air Pollution, Indoor | 2 | 2019 | 30 | 0.660 |
Why?
|
| Vehicle Emissions | 1 | 2019 | 19 | 0.650 |
Why?
|
| Registries | 4 | 2024 | 1388 | 0.620 |
Why?
|
| Women's Health | 2 | 2010 | 130 | 0.620 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2018 | 21 | 0.600 |
Why?
|
| Optic Nerve Glioma | 1 | 2018 | 21 | 0.600 |
Why?
|
| Hypospadias | 4 | 2020 | 81 | 0.600 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 532 | 0.590 |
Why?
|
| Smad6 Protein | 1 | 2017 | 8 | 0.590 |
Why?
|
| Child | 32 | 2024 | 24221 | 0.590 |
Why?
|
| HIV Infections | 8 | 2023 | 1866 | 0.550 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2016 | 37 | 0.540 |
Why?
|
| Genome-Wide Association Study | 6 | 2020 | 1641 | 0.530 |
Why?
|
| Air Pollutants, Radioactive | 1 | 2015 | 5 | 0.510 |
Why?
|
| Radon | 1 | 2015 | 11 | 0.510 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 313 | 0.500 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 162 | 0.490 |
Why?
|
| Texas | 11 | 2024 | 3545 | 0.490 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2019 | 2585 | 0.480 |
Why?
|
| Medically Uninsured | 3 | 2010 | 73 | 0.440 |
Why?
|
| Adolescent | 23 | 2024 | 19093 | 0.430 |
Why?
|
| Child, Preschool | 18 | 2024 | 13878 | 0.430 |
Why?
|
| Herpesvirus 8, Human | 3 | 2023 | 49 | 0.420 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 418 | 0.420 |
Why?
|
| Lymphoma | 1 | 2015 | 322 | 0.400 |
Why?
|
| Adult | 19 | 2024 | 29029 | 0.400 |
Why?
|
| Female | 31 | 2024 | 65443 | 0.380 |
Why?
|
| Parents | 1 | 2018 | 1023 | 0.370 |
Why?
|
| Humans | 44 | 2024 | 123146 | 0.360 |
Why?
|
| Male | 27 | 2024 | 60034 | 0.350 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2024 | 164 | 0.340 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2023 | 194 | 0.340 |
Why?
|
| MicroRNAs | 1 | 2016 | 827 | 0.340 |
Why?
|
| Poverty | 2 | 2010 | 419 | 0.330 |
Why?
|
| Health Status Indicators | 1 | 2010 | 120 | 0.330 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2021 | 226 | 0.320 |
Why?
|
| Anemia | 2 | 2023 | 339 | 0.310 |
Why?
|
| Infant | 15 | 2024 | 12339 | 0.310 |
Why?
|
| Young Adult | 11 | 2024 | 8864 | 0.300 |
Why?
|
| Health Services Accessibility | 2 | 2010 | 594 | 0.290 |
Why?
|
| DNA Methylation | 3 | 2020 | 988 | 0.290 |
Why?
|
| SEER Program | 2 | 2018 | 193 | 0.280 |
Why?
|
| Incidence | 4 | 2018 | 3050 | 0.270 |
Why?
|
| Risk Factors | 9 | 2024 | 10011 | 0.260 |
Why?
|
| Infant, Newborn | 9 | 2024 | 8104 | 0.240 |
Why?
|
| Tanzania | 2 | 2023 | 66 | 0.240 |
Why?
|
| United States | 8 | 2024 | 10627 | 0.240 |
Why?
|
| Advance Care Planning | 1 | 2024 | 38 | 0.230 |
Why?
|
| Cerebellar Neoplasms | 2 | 2017 | 282 | 0.220 |
Why?
|
| Medulloblastoma | 2 | 2017 | 338 | 0.220 |
Why?
|
| Extremities | 1 | 2023 | 82 | 0.220 |
Why?
|
| Endogenous Retroviruses | 1 | 2023 | 17 | 0.220 |
Why?
|
| Terminal Care | 1 | 2024 | 114 | 0.210 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2023 | 16 | 0.210 |
Why?
|
| Exercise | 2 | 2024 | 810 | 0.210 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 868 | 0.210 |
Why?
|
| Minority Groups | 2 | 2018 | 250 | 0.200 |
Why?
|
| Thrombocytosis | 1 | 2022 | 34 | 0.200 |
Why?
|
| Environmental Exposure | 1 | 2024 | 217 | 0.200 |
Why?
|
| Exome | 2 | 2017 | 1041 | 0.200 |
Why?
|
| Odds Ratio | 3 | 2019 | 1243 | 0.190 |
Why?
|
| Life Style | 1 | 2024 | 402 | 0.190 |
Why?
|
| California | 3 | 2010 | 128 | 0.190 |
Why?
|
| Cancer Survivors | 1 | 2024 | 187 | 0.190 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 120 | 0.190 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 230 | 0.180 |
Why?
|
| Middle Aged | 9 | 2024 | 25964 | 0.180 |
Why?
|
| Neoplasms | 3 | 2024 | 2766 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 228 | 0.180 |
Why?
|
| Palliative Care | 1 | 2024 | 428 | 0.180 |
Why?
|
| Women | 2 | 2010 | 15 | 0.170 |
Why?
|
| Interleukin-6 | 2 | 2019 | 393 | 0.170 |
Why?
|
| Leukemia | 1 | 2023 | 376 | 0.170 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2021 | 224 | 0.170 |
Why?
|
| Malnutrition | 1 | 2022 | 196 | 0.170 |
Why?
|
| Malawi | 4 | 2023 | 389 | 0.170 |
Why?
|
| Emigrants and Immigrants | 1 | 2021 | 148 | 0.160 |
Why?
|
| Diacylglycerol Kinase | 1 | 2019 | 15 | 0.160 |
Why?
|
| Social Class | 1 | 2020 | 192 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 430 | 0.160 |
Why?
|
| Metals, Heavy | 1 | 2019 | 18 | 0.160 |
Why?
|
| Health Care Surveys | 2 | 2010 | 284 | 0.160 |
Why?
|
| Neuroblastoma | 1 | 2023 | 509 | 0.150 |
Why?
|
| Air Pollution | 1 | 2019 | 67 | 0.150 |
Why?
|
| Human papillomavirus 18 | 1 | 2017 | 6 | 0.150 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 353 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2020 | 219 | 0.150 |
Why?
|
| Human papillomavirus 16 | 1 | 2017 | 46 | 0.150 |
Why?
|
| Herpesviridae Infections | 1 | 2018 | 142 | 0.140 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 58 | 0.140 |
Why?
|
| Premature Birth | 1 | 2021 | 380 | 0.140 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2016 | 21 | 0.140 |
Why?
|
| Viral Load | 1 | 2018 | 382 | 0.140 |
Why?
|
| Mexico | 1 | 2016 | 178 | 0.130 |
Why?
|
| Cisplatin | 1 | 2017 | 242 | 0.130 |
Why?
|
| Acute Disease | 1 | 2019 | 1090 | 0.130 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2018 | 145 | 0.130 |
Why?
|
| Inhalation Exposure | 1 | 2015 | 36 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 300 | 0.130 |
Why?
|
| Genetic Testing | 2 | 2021 | 995 | 0.130 |
Why?
|
| Chronic Disease | 2 | 2010 | 1167 | 0.120 |
Why?
|
| Housing | 1 | 2015 | 60 | 0.120 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2017 | 234 | 0.120 |
Why?
|
| Family | 1 | 2017 | 579 | 0.110 |
Why?
|
| Pregnancy | 4 | 2021 | 7142 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2017 | 278 | 0.110 |
Why?
|
| Cytokines | 1 | 2019 | 1283 | 0.110 |
Why?
|
| Databases, Genetic | 2 | 2023 | 471 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 518 | 0.110 |
Why?
|
| Aged | 4 | 2024 | 19068 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1680 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2022 | 16000 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2018 | 4705 | 0.110 |
Why?
|
| Risk | 1 | 2015 | 749 | 0.110 |
Why?
|
| Lamivudine | 2 | 2022 | 25 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 866 | 0.100 |
Why?
|
| Genotype | 4 | 2019 | 2540 | 0.100 |
Why?
|
| Smoking | 2 | 2024 | 1031 | 0.100 |
Why?
|
| Genome, Human | 1 | 2018 | 1266 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2024 | 1541 | 0.090 |
Why?
|
| Birth Weight | 2 | 2023 | 336 | 0.090 |
Why?
|
| Marital Status | 1 | 2010 | 34 | 0.090 |
Why?
|
| Income | 1 | 2010 | 133 | 0.080 |
Why?
|
| Vaginal Smears | 1 | 2009 | 51 | 0.080 |
Why?
|
| Employment | 1 | 2009 | 67 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2024 | 12116 | 0.080 |
Why?
|
| Mothers | 2 | 2023 | 350 | 0.080 |
Why?
|
| Office Visits | 1 | 2009 | 76 | 0.080 |
Why?
|
| Health Surveys | 1 | 2010 | 241 | 0.080 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2008 | 1 | 0.080 |
Why?
|
| Educational Status | 1 | 2010 | 270 | 0.080 |
Why?
|
| Blood Cells | 1 | 2019 | 49 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 2047 | 0.080 |
Why?
|
| Mammography | 1 | 2009 | 113 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2009 | 76 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1432 | 0.080 |
Why?
|
| Prognosis | 3 | 2022 | 4505 | 0.080 |
Why?
|
| Obesity | 2 | 2010 | 2226 | 0.080 |
Why?
|
| Gestational Age | 2 | 2023 | 1136 | 0.080 |
Why?
|
| Health Status | 1 | 2009 | 374 | 0.070 |
Why?
|
| CpG Islands | 2 | 2020 | 321 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2017 | 2585 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 404 | 0.070 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 759 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3380 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2009 | 557 | 0.060 |
Why?
|
| Oil and Gas Fields | 1 | 2024 | 9 | 0.060 |
Why?
|
| Clinical Coding | 1 | 2024 | 13 | 0.060 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2024 | 52 | 0.060 |
Why?
|
| Adenine Nucleotides | 1 | 2024 | 41 | 0.060 |
Why?
|
| Arabinonucleosides | 1 | 2024 | 32 | 0.060 |
Why?
|
| Sarcoma, Ewing | 1 | 2024 | 113 | 0.050 |
Why?
|
| Nevirapine | 1 | 2022 | 15 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2023 | 168 | 0.050 |
Why?
|
| Platelet Count | 1 | 2022 | 133 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2024 | 193 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2022 | 229 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2024 | 337 | 0.050 |
Why?
|
| Hepatoblastoma | 1 | 2024 | 178 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 5046 | 0.050 |
Why?
|
| Health Behavior | 1 | 2024 | 381 | 0.050 |
Why?
|
| Causality | 1 | 2021 | 83 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2023 | 540 | 0.050 |
Why?
|
| Weight Gain | 1 | 2023 | 401 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 183 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 171 | 0.040 |
Why?
|
| Virus Replication | 1 | 2023 | 604 | 0.040 |
Why?
|
| Recurrence | 1 | 2024 | 1422 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 30 | 0.040 |
Why?
|
| Arkansas | 1 | 2019 | 56 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2024 | 780 | 0.040 |
Why?
|
| Hazardous Substances | 1 | 2019 | 17 | 0.040 |
Why?
|
| Endemic Diseases | 1 | 2018 | 58 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2019 | 6027 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 659 | 0.040 |
Why?
|
| Virus Activation | 1 | 2018 | 86 | 0.040 |
Why?
|
| Unsafe Sex | 1 | 2017 | 20 | 0.040 |
Why?
|
| Virus Integration | 1 | 2017 | 42 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2021 | 382 | 0.040 |
Why?
|
| Guatemala | 1 | 2017 | 62 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1469 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 137 | 0.040 |
Why?
|
| Canada | 1 | 2017 | 294 | 0.030 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2017 | 88 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2017 | 477 | 0.030 |
Why?
|
| Hearing Loss | 1 | 2017 | 131 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 1213 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 665 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 1993 | 0.030 |
Why?
|
| Mutation | 1 | 2019 | 5773 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 1387 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1796 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 1337 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 1604 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 794 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2019 | 1480 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2529 | 0.020 |
Why?
|
| Prevalence | 1 | 2017 | 2405 | 0.020 |
Why?
|
| Health Care Reform | 1 | 2008 | 50 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1677 | 0.020 |
Why?
|
| Child Health Services | 1 | 2008 | 86 | 0.020 |
Why?
|
| Forecasting | 1 | 2008 | 355 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 4221 | 0.020 |
Why?
|
| Age Factors | 1 | 2008 | 2799 | 0.010 |
Why?
|
PECKHAM-GREGORY's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(215)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(53)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_